Bluejay Diagnostics, Inc. (BJDX) Balance Sheet

The downward trend in total assets suggests that the company is consuming its capital base to fund R&D and licensing obligations. Investors should monitor this trajectory closely, as the lack of revenue generation means the balance sheet is effectively a countdown clock toward the next required capital raise.

While the current ratio of 2.81 appears superficially healthy, it is heavily influenced by the remaining cash balance rather than operational efficiency. This liquidity profile suggests that the company may face severe constraints in its ability to fund future clinical milestones without immediate and potentially dilutive external financing.

The deep negative retained earnings position highlights the significant risk to common equity holders, as the company continues to rely on external capital to bridge its operating losses. This structure suggests that future value creation is entirely contingent upon successful commercialization, as the current equity base is essentially a vehicle for funding R&D.